NatWest Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

NatWest Group’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-6,873	Closed	-$724K	–	157
2015 Q3	$724K	Buy	+6,873	New	+$918K	0.02%	226
2015 Q2	–	Sell	-6,873	Closed	-$857K	–	383
2015 Q1	$857K	Sell	6,873 -1,402	-17%	-$149K	0.01%	237
2014 Q4	$748	Sell	8,275 -9,986	-55%	-$830K	0.01%	248
2014 Q3	$1.32K	Buy	18,261 +1,204	+7%	+$79.1K	0.01%	227
2014 Q2	$1.06M	Buy	17,057 +1,911	+13%	+$115K	0.04%	258
2014 Q1	$1.03M	Sell	15,146 -75	-0.5%	-$5.53K	0.05%	242
2013 Q4	$1.07M	Sell	15,221 -1,487	-9%	-$101K	0.03%	421
2013 Q3	$1.21M	Sell	16,708 -3,007	-15%	-$200K	0.04%	366
2013 Q2	$1.1M	Buy	+19,715	New	+$1.23M	0.02%	452

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

NatWest Group's BMRN Position: Q4 2015 in Review

NatWest Group sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2015, closing a stake of 6,873 shares — an estimated $724K sold.

NatWest Group first reported a position in BMRN in Q2 2013 and held it in 9 quarters. The position peaked at $1.21M in Q3 2013. 388 funds tracked by Wall St. Rank hold BMRN as of Q4 2015.

NatWest Group reported no remaining BioMarin Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
NatWest Group sold 6,873 BioMarin Pharmaceuticals shares in Q4 2015, an estimated $724K.
NatWest Group first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 9 quarters.
NatWest Group's BioMarin Pharmaceuticals position peaked at $1.21M in Q3 2013.
388 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2015.

Based on NatWest Group's 13F filing for Q4 2015, filed 16 Feb 2016.